Clinical Trial Search

Primary: Number of Participants With Acute Respiratory Failure Within the First 7 Days Following Surgery (or Until Hospital Discharge if Occurring First) — 35; 30 Participants

Primary: Adherence — 1; 8; 3 millimeters — p=.037

Primary: Proportion of Patients by Type of IRD — 720; 174; 30; 58 Participants

Primary: Change in Weight — -0.7; -0.4; -0.7; -0.3 Kilograms

Primary: Incident Infection Rate in Participants During the First Year Post-acute Lymphoblastic Leukemia Therapy — 3.60 Events per person-year

Primary: Change in Asthma Control Questionnaire (ACQ) Score — 0.52 score on a scale

Primary: Changes in Emotional Regulation — 54.43; 52.02; 54.47; 60.77 T Score — p=0.003

Primary: Steps Toward Prevention - Autism Community Suicide Prevention: Knowledge & Capacity — 3.98; 4.54; 4.52 Scores on a 5-point scale — p=<0.001

Primary: PrEP Prescriptions — 11; 0 Participants

Primary: Retention — 14; 14 Participants

Primary: Maximum Observed Plasma Concentration (Cmax) of Olanzapine (Extended-release Formulation) — 39.26; 35.62; 29.68 nanograms (ng)/milliliter (mL)

Primary: Matched VE Participants in the Minimum Age Model — 31; 70; 6; 31 Participants

Primary: Change of 1 Point From Baseline in Infra-Orbital Hollows Severity Rated by the Blinded Live Evaluator (BLE) at Week 12 After Last Treatment, Using the TIOHS - Phase 1a…

Primary: Percentage of Placebo Receiving Pediatric Participants With Vaccine Virus Detected in Nasal Swabs After the First Vaccination — 0; 0; 0; 0 percentage of participants

Primary: Percentage of Procedures With at Least One Serious/Not Serious Adverse Event Certainly or Possibly Related to JTIN — 4.0 percentage of procedures